1. Home
  2. RPRX vs STLA Comparison

RPRX vs STLA Comparison

Compare RPRX & STLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$49.61

Market Cap

19.5B

Sector

Health Care

ML Signal

HOLD

Logo Stellantis N.V.

STLA

Stellantis N.V.

HOLD

Current Price

$8.50

Market Cap

19.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPRX
STLA
Founded
1996
2021
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Manufacturing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
19.5B
19.4B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
RPRX
STLA
Price
$49.61
$8.50
Analyst Decision
Strong Buy
Buy
Analyst Count
5
5
Target Price
$51.40
$11.59
AVG Volume (30 Days)
2.5M
21.6M
Earning Date
05-06-2026
02-26-2026
Dividend Yield
1.90%
6.72%
EPS Growth
N/A
N/A
EPS
1.78
N/A
Revenue
$2,378,193,000.00
N/A
Revenue This Year
$38.63
$7.18
Revenue Next Year
$4.73
$3.50
P/E Ratio
$27.80
N/A
Revenue Growth
5.06
N/A
52 Week Low
$31.58
$6.28
52 Week High
$50.08
$12.22

Technical Indicators

Market Signals
Indicator
RPRX
STLA
Relative Strength Index (RSI) 63.62 66.11
Support Level $35.32 $7.07
Resistance Level N/A $10.31
Average True Range (ATR) 0.91 0.22
MACD 0.08 0.12
Stochastic Oscillator 84.32 78.58

Price Performance

Historical Comparison
RPRX
STLA

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About STLA Stellantis N.V.

Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.

Share on Social Networks: